Medicago
Medicago is a Quebec-based biotechnology company that developed plant-based vaccines using a Nicotiana benthamiana molecular-farming platform, primarily serving government health agencies with a now-withdrawn COVID-19 vaccine whose technology assets were acquired by Aramis Biotechnologies in 2023.
- Company typePrivate
- Founded1997
- HeadquartersQuebec, Canada
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medicago does
Medicago was a Canadian biotechnology company founded in 1997 and headquartered in Quebec, focused on the research, development, and commercialization of vaccines using a proprietary plant molecular farming platform based on Nicotiana benthamiana (wild tobacco plant). The platform produces virus-like particles (VLPs) in roughly 20 days, an order-of-magnitude faster than egg- or mammalian-cell-based methods, with lower capital intensity because production leverages agricultural infrastructure rather than purpose-built bioreactors. Medicago's commercial output was a single approved product — a plant-based COVID-19 vaccine that received Canadian regulatory approval during the pandemic but was subsequently withdrawn amid market saturation and the exit of Mitsubishi Chemical Group from pharmaceuticals.
The company's commercial model relied on a single channel: government health-agency procurement, anchored by a C$131.8 million investment from the Government of Canada in October 2020 and earlier equity from the Government of Quebec, Investissement Québec, and life-sciences funds. With only one product, one buyer class, and one principal strategic backer, the business model proved acutely exposed when Mitsubishi departed and COVID demand collapsed. Following withdrawal of the vaccine and Mitsubishi's exit, the company's technology assets were acquired in 2023 by Aramis Biotechnologies, a Quebec City-based startup founded that same year, which has stated a goal of restarting Phase 1–3 clinical trials and commercializing a plant-based influenza vaccine by 2030. Operationally, the original Medicago entity has been delisted (cve:MDG) and effectively ceased independent activity; the platform's future value resides with Aramis rather than the legacy corporate entity.
Medicago firmographics
Firmographics- Name
- Medicago
- Legal name
- Medicago Inc.
- Website
- https://medicago.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Medicago is a Quebec-based biotechnology company that developed plant-based vaccines using a Nicotiana benthamiana molecular-farming platform, primarily serving government health agencies with a now-withdrawn COVID-19 vaccine whose technology assets were acquired by Aramis Biotechnologies in 2023.
- Ownership category
- akta.pro rank
Medicago industry classification
Industry- Product category
- Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD)
Keywords
Where Medicago is headquartered
LocationHeadquarters
- HQ city
- Quebec
- HQ country
- Canada
- HQ region
- North America
Markets served
Medicago business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales
Medicago product offering
Product offeringCore offering
Medicago discovers, develops, and manufactures vaccines and recombinant therapeutic proteins using a proprietary plant-based transient expression platform grown in Nicotiana benthamiana. Its commercial-scale product was a plant-based virus-like-particle COVID-19 vaccine (Covifenz®), authorized for use in Canada in February 2022 and withdrawn from the Canadian market in May 2022 due to COVID-19 vaccine market saturation. The platform also supports development of seasonal flu, rotavirus, norovirus, and HPV vaccine candidates.
Product overview
Medicago was a biopharmaceutical company specializing in plant-based vaccine development. The company's primary product was a plant-based COVID-19 vaccine that used Nicotiana benthamiana plant cells to produce virus-like particles (VLPs). The company developed this technology platform to rapidly produce vaccines in as little as 20 days. Following regulatory approval in Canada and subsequent market withdrawal, the technology assets were acquired by Aramis Biotechnologies for continued development of plant-based influenza vaccines.
Differentiator
Problem solved
Functional benefit
Products and services
- Covifenz® plant-based COVID-19 vaccine A two-dose adjuvanted COVID-19 vaccine composed of recombinant SARS-CoV-2 spike glycoprotein virus-like particles (CoVLP) expressed in Nicotiana benthamiana, formulated with an adjuvant to elicit neutralizing antibody responses against SARS-CoV-2, including Delta and Omicron variants. Sold directly to national and provincial government health authorities in Canada.
- Proficia™ plant-based production platform Proprietary transient-expression manufacturing platform that uses Nicotiana benthamiana plants to produce virus-like particle vaccines and recombinant protein therapeutics. Made available to pharmaceutical partners through licensing and co-development agreements, and used internally by Medicago to manufacture its vaccine pipeline.
Companies that use Medicago
Customer profileSegments1 record
Ideal customer profiles2 records
Medicago technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Medicago partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Aramis BiotechnologiescoreAramis Biotechnologies, a Quebec City-based startup founded in 2023, acquired technology assets from Medicago, which included the technology platform for plant-based vaccine production using Nicotiana benthamiana. Medicago had received approval for a plant-based COVID-19 vaccine in Canada during the pandemic but withdrew it due to market saturation and Mitsubishi's exit from pharmaceuticals.
Scale indicators2 records
Recent moves6 records
Expansion highlights3 records
Medicago competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Medicago social profiles
Digital presenceMedicago financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medicago leadership team
Management profileNumber of profiles
Medicago funding detail
Funding detailFunding overview
Funding rounds7 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medicago M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medicago
What does Medicago do?
Medicago discovers, develops, and manufactures vaccines and recombinant therapeutic proteins using a proprietary plant-based transient expression platform grown in Nicotiana benthamiana. Its commercial-scale product was a plant-based virus-like-particle COVID-19 vaccine (Covifenz®), authorized for use in Canada in February 2022 and withdrawn from the Canadian market in May 2022 due to COVID-19 vaccine market saturation. The platform also supports development of seasonal flu, rotavirus, norovirus, and HPV vaccine candidates.
Is Medicago a public or private company?
Medicago is a private company. It is classified as corporate owned and is currently acquired.
When was Medicago founded?
Medicago was founded in 1997. It employs 501 to 1,000 people.
Where is Medicago based?
Medicago is headquartered in Quebec, Canada, in the North America region.
Does Medicago have an API?
No public API is recorded for Medicago.
What industry is Medicago in?
Medicago's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.